• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

    2/10/22 8:32:47 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCRX alert in real time by email
    SC 13G/A 1 tv01612-pacirabiosciencesinc.htm SCHEDULE 13G/A pacirabiosciencesinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 9)*

    Name of issuer:  Pacira BioSciences Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  695127100

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  695127100

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    84,129

    7.  SOLE DISPOSITIVE POWER

    4,540,561

    8.  SHARED DISPOSITIVE POWER

    125,394

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,665,955

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.47%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Pacira BioSciences Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    5401 West Kennedy Boulevard, Suite 890
    Tampa, FL 33609

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    695127100

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $PCRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PCRX

    DatePrice TargetRatingAnalyst
    1/30/2025$8.00 → $25.00Sell → Hold
    Truist
    8/13/2024$30.00 → $8.00Buy → Sell
    Truist
    8/12/2024$42.00 → $11.00Overweight → Neutral
    Piper Sandler
    8/12/2024$45.00 → $10.00Overweight → Underweight
    JP Morgan
    8/12/2024Outperform → Mkt Perform
    Raymond James
    8/12/2024$37.00 → $14.00Outperform → Sector Perform
    RBC Capital Mkts
    7/3/2024$38.00 → $25.00Overweight → Equal Weight
    Barclays
    3/7/2024$80.00 → $45.00Overweight
    JP Morgan
    More analyst ratings

    $PCRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pacira BioSciences Reports First Quarter 2025 Financial Results

      -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the first quarter of 2025. First Quarter 2025 Financial Highlights Total revenues of $168.9 millionNet product sales of $136.5 million for EXPAREL, $23.3 million for ZILRETTA, and $5.1 million for iovera°Net income of $4.8 million, or $0.10 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $44.1 million See "Non-GAAP Financial Informa

      5/8/25 4:00:00 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis

      -- Data will be featured at EULAR Annual Congress – BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced new data from its ongoing Phase 1 study of its gene therapy candidate PCRX-201 (enekinragene inzadenovec). The data is being presented at the 2025 European Alliance of Associations for Rheumatology (EULAR) Annual Congress, taking place from June 11-14, in Barcelona, Spain. Presentation Title: A Single Intra-articular Injection of the Gene Therapy PCRX-201 Was Safe and Provided Sustained Clinical Benefits for Pa

      5/6/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

      BRISBANE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced an upcoming podium presentation of findings from its Phase 1 study of PCRX-201 (enekinragene inzadenovec), a locally administered gene therapy candidate for osteoarthritis of the knee. The data will be presented at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in New Orleans on May 15. The presentation will highlight how preexisting and treatment-induced neutralizing antibodies (NAbs) impact the therapy's efficacy, safety, and re

      5/2/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pacira BioSciences upgraded by Truist with a new price target

      Truist upgraded Pacira BioSciences from Sell to Hold and set a new price target of $25.00 from $8.00 previously

      1/30/25 7:16:40 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences downgraded by Truist with a new price target

      Truist downgraded Pacira BioSciences from Buy to Sell and set a new price target of $8.00 from $30.00 previously

      8/13/24 7:53:59 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Pacira BioSciences from Overweight to Neutral and set a new price target of $11.00 from $42.00 previously

      8/12/24 8:01:11 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Pacira Announces Updates to Board of Directors

      -- Accomplished Business and Financial Leader, Laura Brege, Appointed Chair -- -- Paul J. Hastings and Andreas Wicki, PhD Retire from Board of Directors -- PARSIPPANY, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that Laura Brege has been appointed Chair of the Board. Former Chair Paul J. Hastings and Andreas Wicki, PhD. have retired from the Board. These changes align with Pacira's ongoing commitment to Board refreshment. With these changes, the Board is composed of nine directors, eight of whom are independent and

      1/30/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO

      Former CEO, Sander van Deventer to become President of R&D Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package Expansion of corporate footprint into the US (Boston) VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241216441837/en/VectorY strengthens Leadership Team with appointment of Jim Scibetta as new CEO (Photo

      12/16/24 7:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $PCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bigal Marcelo bought $20,034 worth of shares (1,512 units at $13.25), increasing direct ownership by 18% to 10,142 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      8/19/24 8:25:55 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Brege Laura bought $12,810 worth of shares (1,000 units at $12.81), increasing direct ownership by 6% to 17,552 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      8/19/24 8:25:46 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Yang Michael J. bought $25,800 worth of shares (2,000 units at $12.90), increasing direct ownership by 38% to 7,230 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      8/14/24 4:35:09 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pacira BioSciences Inc.

      10-Q - Pacira BioSciences, Inc. (0001396814) (Filer)

      5/8/25 4:07:07 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Pacira BioSciences, Inc. (0001396814) (Filer)

      5/8/25 4:06:04 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Pacira BioSciences Inc.

      DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)

      4/29/25 4:11:36 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Slonin Jonathan was granted 93,600 shares, increasing direct ownership by 100% to 187,044 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      2/4/25 6:26:04 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Administrative Officer Williams Kristen was granted 79,200 shares, increasing direct ownership by 77% to 182,112 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      2/4/25 6:25:54 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Lee Frank D. was granted 350,000 shares, increasing direct ownership by 356% to 448,409 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      2/4/25 6:25:44 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

      SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

      1/19/24 2:40:54 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

      SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

      2/14/23 1:31:32 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

      SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

      1/23/23 3:52:35 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Financials

    Live finance-specific insights

    See more
    • Pacira BioSciences Reports First Quarter 2025 Financial Results

      -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the first quarter of 2025. First Quarter 2025 Financial Highlights Total revenues of $168.9 millionNet product sales of $136.5 million for EXPAREL, $23.3 million for ZILRETTA, and $5.1 million for iovera°Net income of $4.8 million, or $0.10 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $44.1 million See "Non-GAAP Financial Informa

      5/8/25 4:00:00 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

      BRISBANE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its first quarter financial results after the close of the U.S. markets on Thursday May 8, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the confer

      4/29/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results

      — Record revenues of $701 million in 2024 — — Full-year GAAP net loss of $100 million and adjusted EBITDA of $224 million — — Conference call today at 4:30 p.m. ET — PARSIPPANY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2024. "Pacira enters 2025 with a sharp focus on executing our 5x30 strategy to accelerate our transition into an innovative biopharmaceutical organization and therapeutic area leader in musculoskeletal pain and adjacencies," said Frank D. L

      2/27/25 4:05:00 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care